Abstract
Treatment of cancer with vaccines is an attractive prospect, but few tumors express suitable target antigens. Idiotypic determinants of the immunoglobulins expressed on the surface of B-cell lymphomas are tumor-specific antigens (TSAs), which can be targeted by immunotherapy [1–4]. Numerous investigators have reported that idiotypic determinants on the variable region of Ig molecules are capable of eliciting idiotype (Id)-specific responses in xenogenic, syngenic, and autologous immunization systems.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
